Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Phase 2 Terminated 5 enrolled F-star Therapeutics, Inc. PRA Health Sciences · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

Timeline

Start: 2019-10-10
Primary completion: 2020-04-02
Completion: 2020-04-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Inarigivir soproxil	Small molecule	400 mg	—
Background	tenofovir alafenamide	Small molecule	25 mg	—

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Summary

Timeline

Drugs

Indications